Anti-beta2 GP-1 screen (Beta 2 Glycoprotein 1) ELISA Kit

Anti–Beta-2 Glycoprotein I (anti-β2GPI) antibodies are autoantibodies directed against β2-glycoprotein I, a plasma protein that binds phospholipids and plays a role in coagulation. These antibodies are a key component of antiphospholipid syndrome (APS), an autoimmune disorder characterized by arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia. Anti-β2GPI antibodies, especially of the IgG and IgM isotypes, contribute to a prothrombotic state by activating endothelial cells, platelets, and complement pathways, leading to increased risk of clot formation and pregnancy complications.

In the clinical setting, anti-β2GPI testing is used alongside anticardiolipin antibodies and lupus anticoagulant as part of the laboratory criteria for APS diagnosis. Persistent positivity on two occasions at least 12 weeks apart is required to confirm the diagnosis. Anti-β2GPI antibodies are also measured in patients with systemic lupus erythematosus (SLE) who are at increased risk for thrombotic events. Clinically, testing helps assess thrombotic risk, guide anticoagulation therapy, and monitor patients at risk for recurrent pregnancy loss or vascular complications.

In research, anti-β2GPI antibodies serve as biomarkers for investigating autoimmune thrombophilia, endothelial dysfunction, and pregnancy complications. They are used in longitudinal studies to identify individuals at risk of developing APS and in mechanistic studies to understand the pathophysiology of antibody-mediated coagulation and vascular injury. Additionally, anti-β2GPI antibodies are evaluated in clinical trials of anticoagulants or immunomodulatory therapies, providing measurable endpoints for autoimmune-mediated thrombotic disorders.

This product is manufactured in Germany by Medipan GmbH.